



Issue of Equity and Total Voting Rights

September 6, 2021

RNS Number : 8949K

MaxCyte, Inc.

06 September 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Issue of Equity

Increase to **Block Listing**

Block Listing Return

and

Total Voting Rights

GAITHERSBURG, MD, September 6, 2021 - MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT, MXCN) ("**MaxCyte**" or the "**Company**"), a leading provider of cell-engineering platform technologies, announces that the Company has issued 128,615 of new common stock of \$0.01 each in the capital of the Company ("Common Stock") pursuant to the recent exercise of stock options and warrants. Of these new common stock, 64,012 common stock have been issued pursuant to the Company's existing AIM block admission facility. Application has been made to admission to trading on AIM of the remaining 64,603 Common Stock ("Admission") with Admission expected to occur on 10 September 2021. The new Common Stock above rank *pari passu* with the Company's existing shares of Common Stock of the company.

Application has also been made for admission to trading on AIM in respect of an additional block listing of 13 million Common Stock to become effective on 10 September 2021 ("New Block Listing"). Pursuant to the New Block Listing, Common Stock may be issued pursuant

to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank *pari passu* in all respects with the Company's existing Common Stock. Following this increase, the total block listing will consist of 13 million Common Stock.

AIM Block Admission Return

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.

a. Name of company

MaxCyte, Inc.

b. Name of scheme(s)

MaxCyte Long Term Incentive Plan

c. Period of return:

From: 22 January 2021

To: 31 August 2021

d. Number and class of securities not issued under scheme

1,000,000 ordinary shares of common stock of \$0.01 each

e. Number of shares issued under scheme during period

921,342 ordinary shares of common stock of \$0.01 each

f. Balance under the scheme not yet issued at the end of the period.

78,658 ordinary shares of common stock of \$0.01 each

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

1,000,000 common stock of \$0.01 each on 5 May 2017

942,900 common stock of \$0.01 each on 27 January 2021

**Please confirm your total issued share capital as at the end of this period.
(If you hold any shares in Treasury state the figure separately);**

As at 31 August 2021, the total issued stock capital of the Company is 100,388,418 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

Treasury shares (if applicable)Nil.....

h. Contact name and telephone number for queries;

Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer
+1 301 944 1660

Date

6 September 2021

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

MaxCyte Inc.	+1 301-944-1660
Doug Doerfler, Chief Executive Officer	
Amanda Murphy, Chief Financial Officer	

<i>Nominated Adviser and Joint Corporate Broker</i>	+44 (0)20 7886 2500
Panmure Gordon	

Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert Dearden

*Joint Corporate
Broker*

+44 (0)20 7260 1000

**Numis Securities
Limited**

James Black /
Duncan Monteith
/ Matthew
O'Dowd

*Joint Corporate
Broker*

+44 (0) 20 7710 7600

Stifel Nicolaus Europe Limited

Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira
Essebiyea
Corporate Broking
Nick Adams

UK IR Adviser

**Consilium
Strategic**

+44 (0)203 709 5700

maxcyte@consilium-comms.com

Communications

Mary-Jane Elliott
Chris Welsh

US IR Adviser

Gilmartin Group

+1 415-937-5400

David Deuchler,
CFA

ir@maxcyte.com

US Media

Relations

+1 410 299-3310

Jamie Lacey-
Moreira

jamielacey@presscommpr.com

PressComm PR,
LLC

relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRDKABDABKDACK